San Donato Hospital
Lung cancer treatment cost in Italy typically includes diagnostic PET/CT scans ranging from $1,200 to $1,700. Primary surgical interventions like lobectomy runs from $25,000 to $40,000, while immunotherapy for lung cancer ranges from $35,000 to $60,000. Total expenses depend on the cancer stage, molecular profile, and hospital tier. Patients often find competitive pricing in Milan and Rome.
Typical Lung Cancer Treatment Costs in Italy
Bookimed Expert Insight: Patients requiring complex thoracic surgery should prioritize centers like San Raffaele in Milan. Professor Giampiero Negri specializes in minimally invasive lung surgery at this IRCCS-accredited research hospital. For those needing advanced radiation, the clinic’s Tomotherapy system provides high-precision targeting. This approach is best for patients seeking academic-level expertise and high surgical volumes exceeding 52,000 operations annually.
| Italy | Turkey | Austria | |
| Tomotherapy | from $32,000 | from $12,000 | from $30,000 |
| Stereotaxic radiosurgery | from $25,000 | from $4,500 | from $17,000 |
| Radiotherapy for lung cancer | from $13,500 | from $4,000 | from $6,864 |
| Proton-beam therapy | from $70,000 | from $70,000 | from $80,000 |
| Pneumonectomy | from $40,000 | from $10,872 | from $50,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Lung cancer treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Lung cancer treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Lung cancer treatment journey.
Professor Di Muzio leads the Radiotherapy Department at Milan's San Raffaele Hospital, specializing in high-precision radiation techniques.
Associate Professor of Thoracic Surgery and Head of Mini-Invasive Thoracic Surgery Unit at San Raffaele Institute – specializes in minimally invasive techniques for lung conditions.
Dr. Gian Carlo Mattiucci directs the Radiation Oncology Unit at Mater Olbia Hospital. He specializes in using precise imaging to optimize radiation treatments for prostate and lung cancers. Dr. Mattiucci serves as a faculty member for the ESTRO Teaching Course. He also holds an assistant professorship at Università Cattolica del Sacro Cuore.
Written by Mariia Mytrofankina
Italy offers world-class lung cancer treatment at specialized IRCCS-accredited research hospitals in Milan and Rome. Leading centers like San Raffaele and the European Institute of Oncology provide multidisciplinary care. They utilize advanced robotic thoracic surgery and high-precision radiotherapy to treat complex pulmonary tumors.
Bookimed Expert Insight: Italian IRCCS-accredited centers are unique because they legally must combine clinical care with research. This ensures patients get access to experimental protocols before they go mainstream. For example, San Raffaele was the first to implement specific stem cell therapies. This integration often leads to higher success rates in rare or resistant lung cancer cases.
Patient Consensus: Patients note that major tumor institutes in Milan and Rome offer exceptional expertise. Many recommend securing an EU health card early to help manage the logistics of decentralized care.
Italian oncology centers utilize robotic systems, high-precision radiation, and molecular therapies to treat lung cancer. Facilities like San Raffaele in Milan employ the da Vinci Xi robotic system for minimally invasive thoracic surgery. This approach reduces recovery times and improves surgical precision for complex lung resections.
Bookimed Expert Insight: While many countries offer standard radiation, Italian research hospitals like San Raffaele integrate Tomotherapy with high-precision hypofraction methods. Professor Nadia Di Muzio coordinates specialized protocols that deliver more intense radiation in fewer sessions. This combination is particularly effective for patients requiring both surgical and radiological interventions in a single treatment plan.
Patient Consensus: Patients often choose clinics in Northern Italy to access proton therapy and robotic surgery faster than through public waitlists. Many note that advanced molecular testing is the key first step to qualifying for the latest targeted therapy trials.
Immunotherapy and targeted therapies are widely available for lung cancer in Italy. These treatments are standard for non-small cell lung cancer (NSCLC). Public hospitals and specialized oncology centers provide them through the national health system. Access follows approval by the Italian Medicines Agency.
Bookimed Expert Insight: Expert centers in Milan and northern Italy handle high patient volumes. San Raffaele alone performs over 52,000 operations annually across all departments. This high surgical and clinical volume often correlates with faster access to molecular testing. Patients can benefit from integrated research and clinical practice at these major institutions.
Patient Consensus: Patients note that getting molecular testing early is vital for unlocking targeted options. While coverage is available nationwide, many share that traveling to northern oncology centers often reduces waiting times.
The 5-year survival rate for lung cancer in Italy is approximately 16% for men and 23% for women. Early diagnosis drastically improves outcomes. Stage I localized tumors show survival rates up to 90%. Advanced stage IV cases typically range between 6% and 10% survival.
Bookimed Expert Insight: Clinical data from centers like San Raffaele in Milan confirms that high-volume surgical expertise impacts outcomes. Associate Professor Dr. Giampiero Negri specializes in mini-invasive thoracic surgery for lung diseases. This approach often leads to faster recovery times compared to traditional open chest surgeries. San Raffaele performs over 52,000 operations annually. This high patient volume is a key quality indicator for complex oncology cases.
Patient Consensus: Patients note that early genetic testing for mutations like EGFR is essential. Accessing targeted therapies like osimertinib in Northern Italian hospitals can significantly extend life expectancy.
International medical tourists face significant legal and clinical barriers when enrolling in lung cancer clinical trials in Italy. While major research centers like San Raffaele in Milan operate as global oncology hubs, most trials require Italian residency or an EU health card. Non-EU patients must navigate strict AIFA regulations and complex medical visa requirements.
Bookimed Expert Insight: While Italy is a leader in thoracic research, its trial system is not traditionally designed for medical tourists. San Raffaele in Milan performs over 52,000 operations annually and holds prestigious IRCCS accreditation. However, patients without EU citizenship often find easier trial access in Germany or Switzerland. These neighboring countries frequently provide more robust infrastructure for international trial participants and English-speaking coordinators.
Patient Consensus: Patients note that paperwork for non-EU citizens can be nearly impossible to complete for clinical trials. Many suggest checking eligibility directly with trial sponsors before traveling to Milan or Rome to avoid rejection.
Lung cancer treatment in Italy relies on IRCCS-accredited research hospitals specialising in personalised medicine. Patients access molecular profiling for targeted therapies, immunotherapies like Keytruda, and robot-assisted thoracic surgery. High-precision radiotherapy systems, including CyberKnife and Tomotherapy, target tumours while sparing healthy tissue.
Bookimed Expert Insight: Italian research hospitals like San Raffaele operate as IRCCS centres. These centres must legally combine clinical care with active research. Dr Nadia Di Muzio and her team have published over 200 studies. This ensures patients receive protocols backed by the latest trial data. This dual-focus environment often provides earlier access to emerging radiotherapy techniques like high-precision hypofractionation.
Patient Consensus: Patients emphasise that lung cancer treatment in Italy starts with detailed molecular testing. These results determine if immunotherapy or targeted drugs are suitable. Experience shows that private care often bypasses the longer wait times found in the public health system.
San Raffaele and the European Institute of Oncology (IEO) are Italy's premier centres for lung cancer treatment. These facilities specialise in robotic thoracic surgery and high-precision radiotherapy. They combine clinical excellence with research to handle complex oncology cases with high success rates.
Bookimed Expert Insight: While many patients focus on general oncology, the best outcomes in Italy often come from IRCCS-accredited research hospitals. These centres, including San Raffaele, receive specific government funding for research. This environment allows specialists like Prof Nadia Di Muzio to offer Tomotherapy and brachytherapy years before they become standard in smaller private clinics.
Patient Consensus: Patients in Italy value the multidisciplinary approach where thoracic surgeons and radiation oncologists collaborate on single cases. Many appreciate that these major Milanese hospitals provide technology like the Da Vinci system alongside research-driven care.
International patients can participate in Italian lung cancer clinical trials. This is common at IRCCS-accredited research hospitals. Eligibility depends on specific trial protocols and histopathological diagnosis. Patients must also be able to travel for frequent monitoring. Many Phase I–III trials for non-small-cell lung cancer provide experimental drugs for free.
Bookimed Expert Insight: Italy is a hub for oncology research. However, clinical eligibility often requires having a local oncologist. Data shows that IRCCS-accredited clinics like San Donato and San Raffaele see over 300,000 patients annually. These centres merge research with daily practice. Patients should confirm if trial sponsors accept diagnostic results from Australian laboratories.
Patient Consensus: Patients say it is vital to check if Australian pathology slides are accepted before travelling. They also recommend verifying if an English-speaking coordinator can assist with monitoring after returning home.